- Home
- XBIT vs MDAI Comparison
XBIT vs MDAI Comparison
Compare XBIT & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | MDAI |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.5M | 55.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | XBIT | MDAI |
|---|---|---|
| Price | $2.53 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 198.0K | ★ 456.5K |
| Earning Date | 11-12-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $23,168,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $60.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.09 | $1.04 |
| 52 Week High | $7.24 | $3.25 |
Technical Indicators
Market Signals| Indicator | XBIT | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 48.74 |
| Support Level | $2.15 | $1.49 |
| Resistance Level | $2.44 | $1.65 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 65.12 | 88.10 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.